secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004579
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron expects Q4 RYTELO revenue ~$45-46M; FY 2024 opex ~$250-260M, cash ~$500M
------------------------------------------------------------------------------

- Preliminary Q4 2024 U.S. RYTELO net revenue expected $45M-$46M, first full quarter of launch.
- FY 2024 operating expenses estimated ~$250M-$260M; cash, equivalents, and securities ~$500M as of Dec 31, 2024.
- Estimates are preliminary, unaudited, subject to change upon completion of financial close and audit.
- RYTELO (imetelstat) is Geron's approved telomerase inhibitor for lower-risk myelodysplastic syndromes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/0000950170-25-004579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/gern-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer